

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2017/12/31	2016/12/31
Balance Sheet		
Current assets		
Total cash and cash equivalents	342,061	309,771
Total Current investments in debt instrument without active market	283,586	455,399
Notes receivable due from related parties, net	0	0
Accounts receivable, net	67,304	23,328
Accounts receivable due from related parties, net	1,533	24,472
Other receivables, net	1,262	2,838
Total current tax assets	2,225	1,907
Total inventories	46,206	50,395
Total prepayments	11,586	19,989
Total other current assets	9,928	48,402
Total current assets	765,691	936,501
Non-current assets		
Non-current financial assets at cost, net	87,000	20,000
Total Non-current investments in debt instrument without active market	0	30,000
Total property, plant and equipment	363,827	315,000
Total intangible assets	1,957	2,342
Deferred tax assets	56,696	39,599
Total other non-current assets	37,628	45,906
Total non-current assets	547,108	452,847
Total assets	1,312,799	1,389,348
Current liabilities		
Total accounts payable	9,567	22,069
Total other payables	114,951	42,658
Other payables to related parties	321	6
Total other current liabilities	2,941	5,728
Total current liabilities	127,780	70,461
Non-current liabilities		
Total deferred tax liabilities	0	473
Total other non-current liabilities	41,153	2,271
Total non-current liabilities	41,153	2,744
Total liabilities	168,933	73,205
Share capital		
Ordinary share	1,121,180	1,120,005
Advance receipts for share capital	604	807
Total share capital	1,121,784	1,120,812
Capital surplus		
Total capital surplus, additional paid-in capital	266,494	621,104
Capital surplus, treasury share transactions	2,812	2,812
Capital surplus, employee share options	29,856	15,695
Total capital surplus	299,162	639,611
Retained earnings		
Total unappropriated retained earnings (accumulated deficit)	-189,469	-356,669
Total retained earnings	-189,469	-356,669
Other equity interest		
Total other equity, others	0	0
Total other equity interest	0	0
Treasury shares	-87,611	-87,611
Total equity	1,143,866	1,316,143
Total liabilities and equity	1,312,799	1,389,348
Number of share capital awaiting retirement	0	0
Equivalent issue shares of advance receipts for ordinary share	36,500	44,000
Number of shares in entity held by entity and by its subsidiaries	2,200,000	2,200,000

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2017/4th	2016/4th
Income Statement		
Total operating revenue	318,637	200,606
Total operating costs	178,828	160,359
Gross profit (loss) from operations	139,809	40,247
Gross profit (loss) from operations	139,809	40,247
Operating expenses		
Total selling expenses	24,780	9,722
Total administrative expenses	41,034	31,155
Total research and development expenses	195,470	217,775
Total operating expenses	261,284	258,652
Net operating income (loss)	-121,475	-218,405
Non-operating income and expenses		
Total other income	24,818	63,259
Other gains and losses, net	-109,058	-2,989
Total non-operating income and expenses	-84,240	60,270
Profit (loss) from continuing operations before tax	-205,715	-158,135
Total tax expense (income)	-17,345	350
Profit (loss) from continuing operations	-188,370	-158,485
Profit (loss)	-188,370	-158,485
Other comprehensive income		
Components of other comprehensive income that will not be reclassified to profit or loss		
Gains (losses) on remeasurements of defined benefit plans	-1,324	-588
Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	-225	-99
Other comprehensive income, net	-1,099	-489
Total comprehensive income	-189,469	-158,974
Basic earnings per share		
Total basic earnings per share	-1.71	-1.45

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2017/4th	2016/4th
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-205,715	-158,135
Profit (loss) before tax	-205,715	-158,135
Depreciation expense	62,448	41,375
Amortization expense	1,026	1,044
Provision (reversal of provision) for bad debt expense	515	4
Interest income	-5,453	-8,075
Share-based payments	15,174	14,686
Loss (gain) on disposal of property, plan and equipment	-99	205
Impairment loss on non-financial assets	2,792	610
Total adjustments to reconcile profit (loss)	76,403	49,849
Decrease (increase) in notes receivable due from related parties	0	71
Decrease (increase) in accounts receivable	-44,491	-4,762
Decrease (increase) in accounts receivable due from related parties	22,939	-24,472
Decrease (increase) in other receivable	1,660	-231
Decrease (increase) in inventories	1,397	-28,378
Decrease (increase) in prepayments	8,106	1,587
Decrease (increase) in other current assets	-101	-465
Total changes in operating assets	-10,490	-56,650
Increase (decrease) in accounts payable	-12,502	2,450
Increase (decrease) in accounts payable to related parties	0	-40
Increase (decrease) in other payable	71,986	7,977
Increase (decrease) in other payable to related parties	315	6
Increase (decrease) in other current liabilities	34,833	-5,890
Increase (decrease) in net defined benefit liability	-63	-54
Total changes in operating liabilities	94,569	4,449
Total changes in operating assets and liabilities	84,079	-52,201
Total adjustments	160,482	-2,352
Cash inflow (outflow) generated from operations	-45,233	-160,487
Income taxes refund (paid)	-317	2,131
Net cash flows from (used in) operating activities	-45,550	-158,356
Cash flows from (used in) investing activities		
Acquisition of investments in debt instrument without active market	-190,487	-250,517
Proceeds from disposal of investments in debt instrument without active market	392,300	654,985
Acquisition of financial assets at cost	-67,000	-20,000
Acquisition of property, plant and equipment	-58,847	-107,471
Proceeds from disposal of property, plant and equipment	114	0
Increase in refundable deposits	-419	0
Decrease in refundable deposits	0	439
Acquisition of intangible assets	-344	-2,522
Increase in other financial assets	-9,108	-51,207
Decrease in other financial assets	47,683	12,593
Increase in prepayments for business facilities	-32,659	-88,369
Increase in other prepayments	-10,780	0
Interest received	5,369	8,360
Net cash flows from (used in) investing activities	75,822	156,291
Cash flows from (used in) financing activities		
Exercise of employee share options	2,018	6,217
Net cash flows from (used in) financing activities	2,018	6,217
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	32,290	4,152
Cash and cash equivalents at beginning of period	309,771	305,619
Cash and cash equivalents at end of period	342,061	309,771
Cash and cash equivalents reported in the statement of financial position	342,061	309,771
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

2017/12/31 Statement of Stockholders' Equity

Accounting Title	Unit: NTS thousand																			
	Ordinary shares	Advance receipts for shares	For share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Exchange differences on translation of foreign financial statements	Gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	Unrealized gains (losses) on available-for-sale financial assets	Gains (losses) on effective portion of cash flow hedges	Gains (losses) on effective portion of hedges of net investments in foreign operations	Change in fair value of financial liability attributable to change in credit risk of liability	Gains (losses) on remeasurements of defined benefit	Evaluation surplus	Equity related to non-current assets classified as held for sale	Other	Total other equity interest	Treasury shares	Total equity	
Equity at end of period	1,120,000	807	1,120,812	638,611	-356,869	-356,869	0	0	0	0	0	0	0	0	0	0	0	0	47,611	1,316,143
Equity at beginning of period after adjustments	1,120,000	807	1,120,812	638,611	-356,869	-356,869	0	0	0	0	0	0	0	0	0	0	0	0	47,611	1,316,143
Equity transfers used to offset accumulated deficits	0	0	0	-296,869	296,869	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Profit (loss)	0	0	0	0	-18,370	-18,370	0	0	0	0	0	0	0	0	0	0	0	0	0	-18,370
Other comprehensive income	0	0	0	0	-1,099	-1,099	0	0	0	0	0	0	0	0	0	0	0	0	0	-1,099
Total comprehensive income	0	0	0	0	-19,469	-19,469	0	0	0	0	0	0	0	0	0	0	0	0	0	-19,469
Share-based payments	1,170	-203	972	18,220	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	17,987
Total increase (decrease) in equity	1,170	-203	972	-346,449	187,200	187,200	0	0	0	0	0	0	0	0	0	0	0	0	0	-132,271
Equity at end of period	1,121,170	604	1,121,794	299,162	-189,469	-189,469	0	0	0	0	0	0	0	0	0	0	0	0	47,611	1,143,863

2016/12/31 Statement of Stockholders' Equity

Accounting Title	Unit: NTS thousand																			
	Ordinary shares	Advance receipts for shares	For share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Exchange differences on translation of foreign financial statements	Gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	Unrealized gains (losses) on available-for-sale financial assets	Gains (losses) on effective portion of cash flow hedges	Gains (losses) on effective portion of hedges of net investments in foreign operations	Change in fair value of financial liability attributable to change in credit risk of liability	Gains (losses) on remeasurements of defined benefit	Evaluation surplus	Equity related to non-current assets classified as held for sale	Other	Total other equity interest	Treasury shares	Total equity	
Equity at end of period	1,116,906	2,211	1,118,201	621,310	-197,666	-197,666	0	0	0	0	0	0	0	0	0	0	0	0	47,611	1,454,214
Effect of retrospective application and retrospective restatement	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Retrospective adjustment of equity attributable to former owner due to reorganization of entities under common control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Equity at beginning of period after adjustments	1,116,906	2,211	1,118,201	621,310	-197,666	-197,666	0	0	0	0	0	0	0	0	0	0	0	0	0	47,611
Profit (loss)	0	0	0	0	-156,465	-156,465	0	0	0	0	0	0	0	0	0	0	0	0	0	-156,465
Other comprehensive income	0	0	0	0	-48	-48	0	0	0	0	0	0	0	0	0	0	0	0	0	-48
Total comprehensive income	0	0	0	0	-156,514	-156,514	0	0	0	0	0	0	0	0	0	0	0	0	0	-156,514
Share-based payments	4,010	-1,404	2,611	18,220	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	20,000
Total increase (decrease) in equity	4,010	-1,404	2,611	18,220	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	19,596
Equity at end of period	1,120,916	807	1,121,812	639,530	-197,666	-197,666	0	0	0	0	0	0	0	0	0	0	0	0	47,611	1,316,143